



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-------------|----------------------|---------------------|------------------|
| 10/600,266 | 06/20/2003 | Fumitoshi Asai | 03337C/HG | 7488 |
| 1933 7590 05/30/2008 FRISHAUF, HOLTZ, GOODMAN & CHICK, PC 220 Fifth Avenue 16TH Floor NEW YORK, NY 10001-7708 | | | | |
| EXAMINER KWON, BRIAN YONG S | | | | |
| ART UNIT | | PAPER NUMBER | | |
| 1614 | | | | |
| MAIL DATE | | DELIVERY MODE | | |
| 05/30/2008 | | PAPER | | |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary**Application No.**

10/600,266

Applicant(s)

ASAI ET AL

Examiner

Brian-Yong S. Kwon

Art Unit

1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 12 May 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-5 is/are pending in the application.
- 4a) Of the above claim(s) is/are withdrawn from consideration.
- 5) ☐ Claim(s) is/are allowed.
- 6) ☒ Claim(s) 1-5 is/are rejected.
- 7) ☐ Claim(s) is/are objected to.
- 8) ☐ Claim(s) are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. .
 3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
- Paper No(s)/Mail Date 05/12/08
- 4) ☐ Interview Summary (PTO-413)
- Paper No(s)/Mail Date
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

DETAILED ACTION

Status of Application

1. Acknowledgement is made of applicants' filing of the instant application as a Request for Continued Examination (RCE) under 37 CFR 1.1114. Claims 1-5 are currently pending for prosecution on the merits.
2. It is noted that the previous indication of allowable claims, in the Notice of Allowability mailed 01/07/2008, has been withdrawn upon reconsideration of the claimed invention.

Information Disclosure Statement

3. Acknowledgement is made of applicant's submitting of the information disclosure statement (IDS) on 05/12/2008. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement (IDS) has been considered by the examiner.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.

Art Unit: 1614

2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 1-3 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bernat et al. (US 5989578) or Uchiyama et al. (Stroke, Vol. 20, No. 12, pp. 1643-1647) in view Asai et al. (Annual Report of Sankyo Research Laboratories, 1999, 51, pp. 1-44).

Bernat or Uchiyama teaches a combination of ADP receptor blocking antiplatelet drug (i.e., clopidogrel or ticlopidogrel) and aspirin that shows the synergistic effects. Bernat discloses 1 to 500mg per clopidogrel or ticlopidogrel to 1 to 500mg per aspirin (column 3, lines 21-28; column 4, lines 18-32; Tables; claims) and Uchiyama whereas Uchiyama discloses 300mg per aspirin and 200 mg per ticlopidine ("Results" and "Discussion).

Asai teaches that CS-747 (which is 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4-5,6,7-tetrahydrothieno[3,2-c]pyridine) is effective as ADP receptor blocking antiplatelet agent without any serious adverse effects and more potent than ticlopidine or clopidogrel (see especially page 10-43).

The teaching of Bernat or Uchiyama mainly differs from the claimed invention in the use of 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4-5,6,7-tetrahydrothieno[3,2-c]pyridine to prepare said combination. To incorporate teaching of Bernat or Uchiyama, would have been obvious in view of Asai who teaches the advantage of using CS-747 (which is 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4-5,6,7-tetrahydrothieno[3,2-c]pyridine) over ticlopidine or clopidogrel for potency consideration and better safety and tolerability profile.

One having ordinary skill in the art would have motivated to select CS-747 (which is 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4-5,6,7-tetrahydrothieno[3,2-c]pyridine with the expectation that substitution of ticlopidogrel or clopidogrel with CS-747 would not significantly alter the analogous property of the compound of the reference having ADP receptor blocking antiplatelet agent while providing better safety and tolerability profile to the patient over ticlopidogrel or clopidogrel. Thus, one would have been motivated to combine these references and make the modification because they are drawn to same technical fields (constituted with same ingredients and share common utilities), and pertinent to the problem which applicant concerns about. MPEP 2141.01(a).

With respect to the instant "ratio by weight of 1:500 to 500:1", those of ordinary skill in the art would have readily optimized effective dosages as determined by good medical practice and the clinical condition of the individual patient. Regardless of the manner of administration, the specific dose may be calculated according to body weight, body surface area or organ size. Further refinement of the calculations necessary to determine the appropriate dosage for treatment involving each of the above mentioned formulations is routinely made by those of

ordinary skill in the art and is within the ability of tasks routinely performed by them without undue experimentation, especially in light of the dosage information disclosed in the cited references.

5. Claims 4-5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bernat et al. (US 5989578) or Uchiyama et al. (Stroke, Vol. 20, No. 12, pp. 1643-1647) in view Asai et al. (Annual Report of Sankyo Research Laboratories, 1999, 51, pp. 1-44)., and further in view of Koike et al. (US 5288726). See rejection above.

The modified teaching of Bernat or Uchiyam mentioned above (Bernat et al. or Uchiyama et al. in view of Asai et al.) includes all that is recited in claims 4-5 except the use of the specific salt form, namely hydrochloride or maleate.

However, it would have been obvious in view of Koike who teaches compounds represented by formula (I) including 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4-5,6,7-tetrahydrothienof[3,2-c]pyridine, wherein said compounds are prepared in pharmaceutically salts thereof including maleate and hydrochloride (abstract; column 13, lines 43-63; column 22, line 19 and Example 23).

One having ordinary skilled in the art would have been motivated to select the claimed compounds in maleate or hydrochloride salt with reasonable expectation of success that preparation of said composition in maleate and hydrochloride salt form would not significantly alter the analogous properties of compound of the reference due to close structural similarity of the compounds.

Conclusion

6. No claim is allowed.
7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Kwon whose telephone number is (571) 272-0581. The examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached on (571) 272-0718. The fax number for this Group is (571) 273-8300.

Any inquiry of a general nature of relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications may be obtained from Private PAIR only. For more information about PAIR system, see <http://pair-direct.uspto.gov>. Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

/Brian-Yong S Kwon/
Primary Examiner, Art Unit 1614